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Abstract
Oxaliplatin-induced peripheral neurotoxicity (OPN) is commonly associated with
peripheralhypersensitivitytocoldsensations(CS)butthemechanismisunknown.
We hypothesized that the transient receptor potential melastatin 8 (TRPM8), a
putativecoldandmentholreceptor,contributestooxaliplatincoldhypersensitivity.
TodeterminewhethertheTRPM8isinvolvedinacuteOPN,varyingconcentrations
of menthol were topically applied to the tongues of healthy subjects (n = 40) and
colorectal cancer patients (n = 36) before and after oxaliplatin administration. The
minimumconcentrationofmentholtoevokeCSatthementholapplicationsitewas
determinedastheCSdetectionthreshold(CDT).Inhealthysubjects,themeanCDT
was0.068.SexandagedifferenceswerenotfoundintheCDT.Inadvancedcolorectal
cancerpatients,themeanCDTsigniﬁcantlydecreasedfrom0.067%to0.028%(P =
0.0039) after the ﬁrst course of oxaliplatin infusions, and this marked CS occurred
inpatientswhohadgrade1orlessneurotoxicity,andgrade2neurotoxicity,butnot
in those with grade 3 neurotoxicity. Further, the mean baseline CDT in oxaliplatin-
treated patients was signiﬁcantly higher than that of chemotherapy-na¨ ıve patients
andhealthysubjects(0.151%vs.0.066%,P =0.0225),suggestingthatacutesensory
changes may be concealed by progressive abnormalities in sensory axons in severe
neurotoxicity, and that TRPM8 is subject to desensitization on repeat stimulation.
Our study demonstrates the feasibility of undertaking CDT test in a clinical setting
to facilitate the identiﬁcation of early neurotoxicity. Moreover, our results indicate
potential TRPM8 involvement in acute OPN.
Introduction
Oxaliplatin-induced peripheral neurotoxicity (OPN) is dele-
terious to patients both in terms of troublesome symptoms
and the need to reduce or discontinue chemotherapy(Adels-
berdgeretal.2000).Oxaliplatin,athird-generationplatinum
analog, causes a unique spectrum of acute peripheral nerve
hyperexcitability that has not been observed in patients re-
ceivingotherplatinumchemotherapeuticagents.Conversely,
chronic oxaliplatin treatment induces an axonal neuropa-
thy that is similar to that observed with other platinum-
based compounds (Lehky et al. 2004). In clinical studies, ap-
proximately 90% of oxaliplatin-treated patients experienced
uniqueacuteOPN,particularlycold-inducedparesthesiathat
is usually triggered by cold exposure and begins in the hands
or feet but sometimes occurs around the mouth or in the
throat(Raymondetal.1998a;Raymondetal.1998b;Grothey,
2003; Ali 2010;). It is an acute transient syndrome that may
begin during drug infusion or within minutes, hours, or 1–2
days after administration but is usually self-limiting, often
disappearing within a few days (Gamelin et al. 2002, 2006).
Recently, a wide repertoire of sensory transduction
molecules that convert external environmental stimuli into
neural activity has been identiﬁed (Basbaum et al. 2009).
For example, the transient receptor potential (TRP) family
of ion channels are the primary detectors of thermal stim-
uli (Jordt et al. 2003), and TRP melastatin 8 (TRPM8) de-
termines whether temperatures are considered cool or cold
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(McKemy et al. 2002; Peier et al. 2002; Daniels and McKemy
2007). However, to date, there is no evidence that TRPM8 is
involved in the mechanisms of acute OPN.
Menthol, a potent TRPM8 agonist, has long been known
to induce or intensify cold sensations by interacting with
the peripheral cold receptor, TRPM8 (McKemy et al. 2002;
Peier et al. 2002; Knowlton et al. 2010). The tongue is a
well-characterized sensory organ, and TRPM8 is present in
sensory lingual nerve ﬁbers that mainly project from the
trigeminalganglionwheretheyfunctionascoldandmenthol
receptors on the tongue (Abe et al. 2005).
On the basis of these observations, we hypothesized that
TRPM8 is involved in the mechanisms of acute OPN, es-
pecially marked sensitivity to cold. We tested this hypothe-
sis by topically applying varying concentrations of menthol,
a TRPM8 agonist, to the patients’ tongue before and after
oxaliplatin infusions to determine their sensitivity to cold
sensation. The minimum concentration of menthol to evoke
cold sensation (CS) at the menthol application site was de-
termined as the cold sensation detection threshold (CDT).
The conventional clinical grading system was used to as-
sess the severity of neurotoxicity in relation to CDT. Patients
also completed self-report ratings of their sensitivity to cold
sensation, and the results of these objective and subjective
ﬁndings were compared.
Materials and Methods
Subjects and treatment regimen
A total of 76 subjects were enrolled in this study: 40 healthy
subjects (24 women, 16 men; median age, 54 years; range,
22–85) and 36 patients (22 women, 14 men; median age,
57 years; range, 33–80) with advanced-stage colorectal can-
cer who received standard oxaliplatin in combination with
infusional 5-ﬂuorouracil/leucovorin (FOLFOX) as a ﬁrst-
line treatment. In the FOLFOX regimens, oxaliplatin (mod-
iﬁed FOLFOX 6, 85 mg/m2) was given intravenously over
2 h on day 1 in conjunction with leucovorin (200 mg/m2)
and followed by a 5-ﬂuorouracil (5-FU) bolus injection
(400 mg/m2), repeated every 2 weeks. A continuous 24-h
infusion of 5-FU (600 mg/m2) was given over days 1 and 2.
On day 2, leucovorin (200 mg/m2; over 2 h) and 5-FU bolus
(400 mg/m2) were given intravenously.
Thesubjectsdidnotconsumeanyspicyfood1daypriorto
testing.Theywerealsoaskedtorefrainfromeating,drinking,
chewinggum,brushingtheirteeth,andusingmouthwashfor
2 h before testing, and we veriﬁed that the participants had
observed these restrictions at the beginning of each session.
The present study was conducted in accordance with
the Declaration of Helsinki for the care for human stud-
ies adopted by the Ethics Committee of Higashi-Asahikawa
Hospital. All patients provided written informed consent.
Assessment of menthol in experiments 1
and 2
A solution of 5% L-menthol (from dry crystals; MERCK,
Tokyo, Japan) was prepared in warm distilled water (41◦C)
at the time of application, and this solution was further di-
luted in warm distilled water to yield menthol solutions of
0.005%, 0.01%, 0.05%, 0.1%, 0.5%, and 1% (0.32 mM, 0.64
mM, 3.2 mM, 6.4 mM, 32 mM, and 64 mM, respectively).
These solutions were topically applied with a cotton swab to
the dorsal anterior tongue in two experiments (Fig. 1a). In
experiment 1, the six different menthol solutions were ad-
ministeredtohealthysubjectsandpatientswithcoloncancer
prior to oxaliplatin exposure, and their subjective ratings of
coldsensitivitywererecorded.Inexperiment2,patientswere
examined for alterations in the menthol-induced cold sensa-
tions before and 5–6 h after the patients receiving individual
oxaliplatin infusions. The menthol concentrations used in
this study were based on a previous human study (Albin
etal.2008).Thevehiclecontrol(warmeddistilledwater)was
applied in the same manner.
Both experiments were performed in a room maintained
at a constant temperature (22 ± 1◦C) and a relative humid-
ity of 55 ± 5%. The menthol testing was performed by two
investigators (TK and MS) on all participants. Neither the
individuals nor the investigator were aware of whether men-
thol or the vehicle was applied ﬁrst because the substances
were encoded by a technical assistant.
Cold sensations and Cold sensation
detection threshold
The highest and lowest concentrations of the menthol solu-
tions were set at 1% and 0.005%, respectively. Starting at the
lowest and increasing to the highest menthol concentration,
the solutions were applied with an interstimulus interval of
10 sec. For each stimulus, the subject was instructed to push
ab u t t o na ss o o na sh eo rs h ed e t e c t e daC S( C D T) .T h eC D T
was considered the minimummenthol concentration. When
no threshold was obtained, the highest concentration tested
(1%) was entered as the threshold value.
Assessment of neurotoxicity
The National Cancer Institute Common Terminology Cri-
teria for Adverse Events (CTCAE) version 3.0 was used to
evaluate the severity of neurotoxicity: grade 1 (mild), loss
of deep tendon reﬂexes or paresthesia not interfering with
function;grade2(moderate),sensoryalterationorparesthe-
sia interfering with function but not activities of daily living;
grade 3 (severe), sensory alteration or paresthesia interfering
with activities of daily living; and grade 4, disabling (Trotti
et al. 2003).
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Figure 1. Effects of menthol on cold sensation and the detection threshold in healthy human subjects. (a) The menthol solution was topically applied
with a cotton swab to the dorsal anterior tongue. (b) The mean baseline cold sensation detection thresholds (CDTs) in healthy human volunteers (n =
40) were 0.01% (1 of 40 subjects), 0.05% (26 of 40), and 0.1% (13 of 40). The overall mean CDT was 0.068 ± 0.026% (mean ± SD). (c) Signiﬁcant
sex difference in mean baseline CDT was not found. (d) Signiﬁcant age difference in mean baseline CDT was not found. Cross is the mean of CDT.
Statistics
The effects of oxaliplatin were analyzed by the nonparamet-
ric Wilcoxon t-test for paired samples. In all of the statis-
tical analyses, signiﬁcance was determined using an alpha
l e v e lo f0 . 0 5 .A l ls t a t i s t i c a lp r o c e d u r e sw e r ep e r f o r m e du s i n g
the IBM-SPSS software package version 18.0J for Windows
(Tokyo, Japan) and the GraphPad Prism 4 statistics program
(GraphPad Software, Inc., San Diego, CA).
Results
Effects of menthol on CS and CDT in healthy
human subjects and patients with colon
cancer (experiment 1)
All subjects noticed a signiﬁcant feeling of coldness at the
menthol application site. The CS occurred within the ﬁrst
3 sec, reached an intensity plateau at approximately 5 sec
and then disappeared within 10 sec. The intensity of the CS
increased in a dose-dependent manner. None of the subjects
experienced a CS when the vehicle control was applied. The
meanbaselineCDTsinhealthyhumanvolunteerswere0.01%
(1of40subjects),0.05%(26of40),and0.1%(13of40).The
mean CDT was 0.068 ± 0.026% (SD) (Fig. 1b). To assess
reproducibility, 40 healthy subjects were retested, and their
CDTswerefoundnottodiffersigniﬁcantlyfromtheprevious
testing. Signiﬁcant sex and age differences in mean baseline
CDTs were not found as well (Fig. 1c and d). No serious
adverse events occurred during the study and all doses of
m e n t h o lw e r ew e l lt o l e r a t e d .
The mean CDT in patients with colon cancer who had
never received any chemotherapy was 0.067 ± 0.025% (n =
12). No signiﬁcant difference in mean baseline CDT was
observed between healthy subjects and patients with colon
cancer.Inaddition,noseriousadverseeventsoccurredduring
the study and all doses of menthol were well tolerated.
Changes in the CDT before and after
oxaliplatin administration (experiment 2)
Figure 2a shows the CDTs that were obtained before and af-
ter the ﬁrst oxaliplatin administration in patients who had
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Figure 2. Changes in the cold sensation detection threshold (CDT) before and after oxaliplatin administration. (a) The CDT was determined by
applying menthol before and after the ﬁrst oxaliplatin administration. The CDT signiﬁcantly decreased from 0.067 ± 0.025% (mean ± SD) to 0.028 ±
0.029% (n = 12, P = 0.0025). (b) Changes in the CDT before and after oxaliplatin administration in patients previously treated with oxaliplatin. The
CDT signiﬁcantly decreased from 0.151 ± 0.263% to 0.083 ± 0.198% (n = 24, P = 0.0004). (c) The mean baseline CDT was signiﬁcantly higher in
patients previously treated with oxaliplatin (n = 24) than in untreated subjects (n = 52) (0.151% vs. 0.066%, P = 0.0225). (d) The CDT was measured
before and after oxaliplatin was administered to patients who had grade 1 or less neurotoxicity. The CDT signiﬁcantly decreased from 0.073± 0.034%
to 0.028 ± 0.021% (n = 9, P = 0.0126). (e) The CDT was measured before and after oxaliplatin was administered to patients who had grade 2
neurotoxicity. There was no signiﬁcant difference in the CDTs (n = 8; before, 0.183 ± 0.332%; after, 0.036 ± 0.033%; P = 0.022). (f) The CDT was
obtained before and after oxaliplatin was administered to patients who had grade 3 neurotoxicity. There was no signiﬁcant difference in the CDTs
(n = 7; before, 0.214 ± 0.347%; after, 0.209 ± 0.351%; P = 1.0). Cross is the mean of CDT.
never received chemotherapy. All but one patient were hy-
persensitive to menthol as indicated by a signiﬁcant decrease
intheCDTfrom0.067±0.025%to0.028±0.029%(n=12,
P = 0.0025). The CDTs were also measured before and after
oxaliplatinadministrationinpatientswhohadpreviouslyre-
ceived oxaliplatin (n = 24, median, 330 mg/m2;r a n g e ,8 5−
2450 mg/m2). Under these conditions, the CDT signiﬁcantly
decreased from 0.151 ± 0.263% to 0.083 ± 0.198% (n =
24, P = 0.0004) (Fig. 2b). Taken together, these ﬁndings
show that the mean baseline CDT was signiﬁcantly higher
in patients previously treated with oxaliplatin (n = 24) than
in untreated subjects (n = 52) (0.151% vs. 0.066%, P =
0.0225).
When the relationship between the CDTs and the CTCAE
neurotoxicityratingsinoxaliplatin-treatedpatientswaseval-
uated, the CDTs were found to be signiﬁcantly decreased in
patients who had grade 1 or less neurotoxicity (from 0.073%
to 0.028%) (n = 9, P = 0.0126) (Fig. 2d), and grade 2 (from
0.183% to 0.036%) (n = 8, P = 0.022) (Fig. 2e), but not in
those with grade 3 neurotoxicity (from 0.214% to 0.209%)
(n = 7, P = 1.0) (Fig. 2f).
Discussion
Our results indicate a potential correlation between TRPM8
activity and OPN, especially in acute hypersensitivity to CS,
and that acute changes in CDT may facilitate the identiﬁca-
tion of early OPN. In chemotherapy-na¨ ıve patients, signif-
icant sensitivity to topical menthol developed after the ﬁrst
oxaliplatin infusion, suggesting that oxaliplatin had indeed
induced cold hypersensitivity. In contrast, patients with pre-
vious oxaliplatin exposure showed reduced cold hypersensi-
tivity. With regard to the relationship between the CDT and
neurotoxicity grade, we found that mild or moderate neuro-
toxicity was associated with signiﬁcant changes in the CDT,
while severe neurotoxicity was not associated with marked
changes in the CDT. Whether the CDT remains unaltered in
oxaliplatin-treatedpatientswhodonotdevelopOPNdespite
chronic oxaliplatin exposure requires further investigation.
Nonetheless,theseﬁndingssuggestthattheCDTisasensitive
marker of early oxaliplatin-induced sensory disturbances.
Menthol activates the cold-transducing Ca2+ ion channel
TRPM8 and increases cold-evoked currents (McKemy et al.
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2002; Peier et al. 2002), and TRPM8 is naturally expressed
sensory neurons (Reid et al. 2002; Abe et al. 2005; Kobayashi
et al. 2005; Madrid et al. 2006). These TRPM8-expressing
sensory neurons project into the superﬁcial laminae of the
spinal cord dorsal horn (Dhaka et al. 2008; Wrigley et al.
2009) that contains cold-sensitive neurons that project into
the spinothalamic tract (Craig and Dostrovsky 2001). Thus,
the cold-induced paresthesias after oxaliplatin administra-
tion that were accentuated by menthol might be mediated
via the activation of TRPM8-expressing innocuous cold re-
ceptors, assuming that the receptors access central neurons.
Although the precise mechanisms underpinning OPN are
still uncertain, this study may serve as an entry point in
furthering the mechanistic understanding of OPN. Oxali-
platinhasalsobeenshowntomodifyintracellularCa2+ han-
dling within the cell bodies of cultured neurons (Grolleau
et al. 2001). A more recent study cited a possible mechanism
for some of the oxaliplatin-induced effects that is related to
the modiﬁcation of surface charges around the ion chan-
nel: either due to extracellular Ca2+ chelation or binding of
a charged biotransformation product of oxaliplatin to the
channel (Broomand et al. 2009). In addition, the prospec-
tive CONcePT study conﬁrmed that OPN could be strongly
attenuated by pre- and post-treating patients with Ca2+ and
Mg2+ infusions(Gamelinetal.2008).Theseﬁndingssuggest
amodeofactionthatinvolvesaCa2+-dependentmechanism
in OPN. Therefore, the Ca2+ ion channel TRPM8 appears to
be a good candidate for understanding the Ca2+-dependent
mechanism in OPN.
The TRP ion channel family consists of approximately 28
mammalian cation channels (Gaudet, 2008; Talavera et al.
2008; Eid and Cortright, 2009) that are involved in a wide
range of physiological and pathophysiological processes in-
cluding taste, thermosensation, pain, and cell cycle regula-
tion. The TRP ion channels present a novel mechanism for
controlling Ca2+ transients in human neurons and represent
potentialtargetsforregulatingneuriteproliferationandout-
growth. Recent studies have shown that regulating TRPM8
ion channels may be a way of controlling Ca2+ transients
in human neurons. We, therefore, hypothesized that oxali-
platin could alter calcium-sensitive voltage-gated Na chan-
nels through a pathwaythat involves Ca2+ ions that are likely
mobilized by TRPM8.
Several limitations should be considered in light of our
results. Firstly, we did not conduct additional follow-up of
CDT after oxaliplatin infusion. Such data would provide a
context for the length of time it takes for the CDTs to return
to normal and would be very useful from a clinical transla-
tionstandpointto approximatetheoutcomeofpatientsafter
oxaliplatin infusion. This approach will be incorporated into
our next protocol. Second, we compared our CDT ﬁndings
against the CTCAE grading system that is a gross general
measure of neuropathy impairment (Trotti et al. 2003) that
precludes speciﬁc measurementof cold allodynia symptoms.
Hence,ourmentholtestingneedsvalidationagainstatesting
method that provides an objective evaluation of cold allo-
dynia/parasthesia, preferably the gold standard of CS, such
as quantitative sensory testing. The validation of the men-
thol testing using quantitative sensory tests will be one of the
important future studies. In addition, although our healthy
subjects and chemotherapy-na¨ ıve patients were similar in
age, sex, and baseline CDTs, having colon cancer patients
as controls rather than healthy volunteers would have estab-
lishedequivalencyatbaselinebyaccountingforthepotential
inﬂuence of cancer-speciﬁc changes on CDTs. Future stud-
ies would beneﬁt from conducting additional evaluations
of CDTs after oxaliplatin infusion, performing quantitative
sensorytesting,andusingpatientswithcoloncancerwithout
OPN as controls.
The present data show that menthol may be used to deter-
mine and evaluate the neurotoxicity severity score, although
the methodology using menthol has not been ﬁrmly estab-
lished. Interestingly, patients with prior oxaliplatin exposure
had signiﬁcantly elevated CDT at baseline, and patients with
grade 3neurotoxicitydid notshow signiﬁcantchangesin the
CDTbeforeandafteroxaliplatinadministration.Theseﬁnd-
ings suggest that TRM8 may be associated with the chronic
stageofOPN.Unfortunately ,inthisstudy ,thesepatientswere
not prospectively monitored for changes in the CDT during
and after a long period of oxaliplatin treatment therefore, we
could not conﬁrm whether or not the CDT increased with
OPN progression. A prospective, multicenter, randomized,
double-blind study is needed to investigate the possibility of
C D Ta sad i a g n o s t i cm a r k e rf o rO P N .
Inconclusion,ourﬁndingsindicatethatOPNmaybeasso-
ciated with TRPM8 in acute hypersensitivity to CS, and that
additional studies on TRPM8 will enhance our understand-
ing of the mechanisms of OPN. Further, our study demon-
strates the feasibility of undertaking CDT test in a clinical
setting to facilitate the identiﬁcation of early neurotoxicity,
although larger trials need to be conducted to conﬁrm our
ﬁndings.
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